Implementation of Universal Tumor Screening of Colorectal Cancer for Detection of Lynch Syndrome at a Hispanic-Rich County Hospital

被引:2
作者
Snedden, Tyler W. [1 ]
McCracken, Andrew [2 ]
Vaidyanathan, Anusha [1 ]
Taranova, Anna [2 ]
Villarreal, Roberto [2 ]
Qamar, Samina [1 ]
Arora, Sukeshi Patel [1 ]
机构
[1] Univ Texas Hlth San Antonio, Mays Canc Ctr, San Antonio, TX USA
[2] Univ Hlth Syst, San Antonio, TX USA
基金
美国国家卫生研究院;
关键词
MICROSATELLITE INSTABILITY; INSURANCE STATUS; IMMUNOHISTOCHEMISTRY; STRATEGIES; PROGRAMS; CARRIERS;
D O I
10.1200/JOP.19.00508
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
INTRODUCTION:In 2014, a reflexive screening protocol for Lynch syndrome (LS) via an immunohistochemistry (IHC) assay was shown to be cost-effective; however, the screening rates at a predominant Hispanic-rich institution are unclear. We hypothesized that implementation of a universal tumor screening (UTS) protocol requiring screening for LS via IHC in patients with newly diagnosed colorectal cancer (CRC) at our Hispanic-rich institution would improve detection of LS by increasing screening rates.METHODS AND MATERIALS:This is a retrospective analysis of screening rates of 3 sequential cohorts of newly diagnosed patients with CRC between January 2012 and April 2016 at the University Health System and with follow-up at National Cancer Institute-designated Mays Cancer Center at University of Texas Health San Antonio. Cohort 1 consisted of patients screened using old screening guidelines (PRE). Cohort 2 consisted of patients screened when treating clinicians were receiving education on the new protocol (PERI). Cohort 3 consisted of patients screened after implementation of the UTS protocol (POST).RESULTS:The majority of 312 patients were Hispanic (62.5%), 18.1% were < 50 years, and 81.9% were <greater than or equal to> 50 years of age (median age, 57 years). Of patients with CRC screened for LS via IHC, the PRE, PERI, and POST cohorts had screening rates of 31%, 64%, and 58%, respectively. We found significant differences when comparing the PRE with POST sequential cohorts (P < .01).CONCLUSION:The quality of Lynch syndrome-related family histories and screening rates were significantly improved after implementation in our Hispanic-rich population. Future studies are warranted to provide insight into clinical effects of increased screening, provider and patient surveillance, and screening-related systemic barriers.
引用
收藏
页码:598 / +
页数:11
相关论文
共 50 条
  • [41] Lower prevalence of Lynch syndrome in colorectal cancer patients in a Japanese hospital-based population
    Kumamoto, Kensuke
    Ishida, Hideyuki
    Suzuki, Okihide
    Tajima, Yusuke
    Chika, Noriyasu
    Kuwabara, Koki
    Ishibashi, Keiichiro
    Saito, Katsuharu
    Nagata, Koji
    Eguchi, Hidetaka
    Tamaru, Junichi
    Iwama, Takeo
    SURGERY TODAY, 2016, 46 (06) : 713 - 720
  • [42] Point: Justification for Lynch Syndrome Screening Among All Patients With Newly Diagnosed Colorectal Cancer
    Hampel, Heather
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (05): : 597 - 601
  • [43] Tumor microsatellite instability and clinicopathologic features in Iranian colorectal cancer patients at risk for Lynch syndrome
    Zeinalian, Mehrdad
    Hashemzadeh-Chaleshtori, Morteza
    Salehi, Rasoul
    Kazemi, Mohammad
    Emami, Mohammad Hassan
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2015, 20 (02): : 154 - 160
  • [44] Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: From the revised Bethesda guidelines to a universal approach
    Morrison, Jane
    Bronner, Mary
    Leach, Brandie H.
    Downs-Kelly, Erinn
    Goldblum, John R.
    Liu, Xiuli
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2011, 46 (11) : 1340 - 1348
  • [45] Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer
    Bruegl, Amanda S.
    Ring, Kari L.
    Daniels, Molly
    Fellman, Bryan M.
    Urbauer, Diana L.
    Broaddus, Russell R.
    CANCER PREVENTION RESEARCH, 2017, 10 (02) : 108 - 115
  • [46] Identifying patients with Lynch syndrome using a universal tumor screening program in an integrated healthcare system
    Philip R. Crain
    Jamilyn M. Zepp
    Sara Gille
    Lindsay Jenkins
    Tia L. Kauffman
    Elizabeth Shuster
    Katrina A.B. Goddard
    Benjamin S. Wilfond
    Jessica Ezzell Hunter
    Hereditary Cancer in Clinical Practice, 20
  • [47] Rates and outcomes of testing for lynch syndrome in a national colorectal cancer screening programme
    Cudmore, Jane
    Kumar, Lakshman
    O'Morain, Neil
    Cullen, Garrett
    Horgan, Gareth
    Aird, John
    Sheahan, Kieran
    Winter, Desmond C.
    Kennelly, Rory
    Leyden, Jan
    CANCER EPIDEMIOLOGY, 2023, 82
  • [48] Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting
    Clarke, Elizabeth V.
    Muessig, Kristin R.
    Zepp, Jamilyn
    Hunter, Jessica E.
    Syngal, Sapna
    Acheson, Louise S.
    Wiesner, Georgia L.
    Peterson, Susan K.
    Bergen, Kellene M.
    Shuster, Elizabeth
    Davis, James V.
    Schneider, Jennifer L.
    Kauffman, Tia L.
    Gilmore, Marian J.
    Reiss, Jacob A.
    Rope, Alan F.
    Cook, Jennifer E.
    Goddard, Katrina A. B.
    FAMILIAL CANCER, 2019, 18 (03) : 317 - 325
  • [49] Routine Molecular Analysis for Lynch Syndrome Among Adenomas or Colorectal Cancer Within a National Screening Program
    Goverde, Anne
    Wagner, Anja
    Bruno, Marco J.
    Hofstra, Robert M. W.
    Doukas, Michael
    van der Weiden, Marcel M.
    Dubbink, Hendrikus J.
    Dinjens, Winand N. M.
    Spaander, Manon C. W.
    GASTROENTEROLOGY, 2018, 155 (05) : 1410 - 1415
  • [50] Identifying factors and causal chains associated with optimal implementation of Lynch syndrome tumor screening: An application of coincidence analysis
    Cragun, Deborah
    Salvati, Zachary M.
    Schneider, Jennifer L.
    Burnett-Hartman, Andrea N.
    Epstein, Mara M.
    Hunter, Jessica Ezzell
    Liang, Su-Ying
    Lowery, Jan
    Lu, Christine Y.
    Pawloski, Pamala A.
    Schlieder, Victoria
    Sharaf, Ravi N.
    Williams, Marc S.
    Rahm, Alanna Kulchak
    GENETICS IN MEDICINE, 2024, 26 (10)